Univariate analysis of predictors of combined end-point (death or hospitalization for heart failure).

<p>The table shows selected characteristics, which were included in the univariate regression analysis. All variables, that approached statistical significance (p<0.1) were included in the multivariate stepwise logistic regression model.</p><p>Troponin peak – peak troponin level during hospitalization, AF – the presence of atrial fibrillation at admission or anytime during index hospitalization, STEMI – myocardial infarction with ST-segment elevation, BMI – body mass index, Glucose – glucose at admission, ALT – alanine aminotransferase, AST – aspartate amino transferase, LV EF – left ventricular ejection fraction, CAD severity – the extension of coronary artery disease, Complete revascularization – the absence of any stenosis of 50% or more in at least one coronary artery at discharge, Procedural difficulties – the combination of slow flow, no reflow od side branch occlusion during PCI.</p

Kaplan – Meier survival curves event rate in patients grouped according to calculated optimal cut-off value of TRAIL.

<p>Patients with TRAIL concentrations up to 44.6 ng/mL are shown as a solid curve, patients with TRAIL concentrations higher than 44.6 ng/mL are shown as a dotted curve. P<0.001 (log rank test).</p

Receiver-operating characteristic curve for the concentration of soluble TRAIL in relation to the primary end-point (death and heart failure).

<p>The closed black dot on the curve shows the concentration of TRAIL (44.6 ng/mL) with the optimal combination of sensitivity and specificity.</p

Serum concentration of soluble TRAIL.

<p>Data are expressed as median with interquartile ranges. Statistical comparison was done by Wilcoxon test.</p

Data_Sheet_1_Trends in outcomes of women with myocardial infarction undergoing primary angioplasty—Analysis of randomized trials.PDF

BackgroundSex- and gender-associated differences determine the disease response to treatment.AimThe study aimed to explore the hypothesis that progress in the management of STE-myocardial infarction (STEMI) overcomes the worse outcome in women.Methods and resultsWe performed an analysis of three randomized trials enrolling patients treated with primary PCI more than 10 years apart. PRAGUE-1,-2 validated the preference of transport for primary PCI over on-site fibrinolysis. PRAGUE-18 enrollment was ongoing at the time of the functional network of 24/7PCI centers, and the intervention was supported by intensive antiplatelets. The proportion of patients with an initial Killip ≥ 3 was substantially higher in the more recent study (0.6 vs. 6.7%, p = 0.004). Median time from symptom onset to the door of the PCI center shortened from 3.8 to 3.0 h, p 6 h was still significant (22.3 vs. 27.2% in PRAGUE-18). There was an increase in probability for an initial TIMI flow >0 in the later study (1.49 [1.0–2.23]), and also for an optimal procedural result (4.24 [2.12–8.49], p ConclusionThe prognosis of women with MI treated with primary PCI improved substantially with 24/7 regional availability of mechanical reperfusion, performance-enhancing technical progress, and intensive adjuvant antithrombotic therapy. A major modifiable hindrance to achieving this benefit in a broad population of women is the timely diagnosis by health professional services.</p

Antithrombotic therapy of patients with atrial fibrillation discharged after major non-cardiac surgery. 1-year follow-up. Sub-analysis of PRAGUE 14 study

<div><p>Background</p><p>The study investigated the discharge antithrombotic medication in patients with atrial fibrillation (AF) after major non-cardiac surgery and the impact on one-year outcomes.</p><p>Methods</p><p>A subgroup of 366 patients (mean age 75.9±10.5 years, women 42.3%, acute surgery 42.9%) undergoing major non-cardiac surgery and having any form of AF (30.6% of the total population enrolled in the PRAGUE-14 study) was followed for 1 year.</p><p>Results</p><p>Antithrombotics (interrupted due to surgery) were resumed until discharge in 51.8% of patients; less frequently in men (OR 0.6 (95% CI 0.95 to 0.35); p = 0.029), and in patients undergoing elective surgery (OR 0.6 (95% CI 0.91 to 0.33); p = 0.021). Dual antiplatelet therapy was resumed more often (91.7%) in comparison to aspirin monotherapy (57.3%; p = 0.047), and vitamin K antagonist (56.3%; p = 0.042). Patients with AF had significantly higher one-year mortality (22.1%) than patients without AF (14.1%, p = 0.001). The causes of death were: ischaemic events (32.6% of deaths), bleeding events (8.1%), others (N = 51; 59.3%, 20 of them died due to cancer). Non-reinstitution of aspirin until discharge was associated with higher one-year mortality (17.6% vs. 34.8%; p = 0.018).</p><p>Conclusion</p><p>Preoperatively interrupted antithrombotics were re-administrated at discharge only in half of patients with AF, less likely in male patients and those undergoing elective surgery. The presence of AF was recognized as a predictor of one-year mortality, especially if aspirin therapy was not resumed until discharge.</p><p>Trial registration</p><p>ClinicalTrials.gov <a href="https://clinicaltrials.gov/ct2/show/NCT01897220" target="_blank">NCT01897220</a></p></div

One-year survival of patients with AF after non-cardiac surgery.

<p>One-year survival of patients with AF after non-cardiac surgery.</p

Baseline characteristics of PRAGUE 14 study population according to presence of AF.

<p>Baseline characteristics of PRAGUE 14 study population according to presence of AF.</p

Baseline characteristics of patients with AF according to (not) re-administration of aspirin and VKA until hospital discharge.

<p>Baseline characteristics of patients with AF according to (not) re-administration of aspirin and VKA until hospital discharge.</p

One-year survival of patients on aspirin after non-cardiac surgery.

<p>One-year survival of patients on aspirin after non-cardiac surgery.</p